Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Biopharma S.P.R.L.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject is newly prescribed Neupro and is expected to commence Neupro treatment. Historical Neupro treatment is permitted
Informed Consent form (ICF) is signed and dated by the subject, before any study-related procedures
Subject is considered reliable and capable of adhering to the protocol, visit schedule, completion of the diary, and using Kinesia devices according to the judgment of the Investigator
Male or female subject, \>=18 years of age at the time of the Screening Visit
Subject has Parkinson's disease, defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: tremor at rest, rigidity or impairment of postural reflexes, and without any other known or suspected cause of Secondary Parkinsonism
Subject experiences motor symptoms associated with Parkinson's disease that are not sufficiently controlled by current therapy. The average of the triplicate resting tremor scores and triplicate finger tapping scores from Kinesia-ONE™ (6 scores in total) must be \>1.0
You may not be if
Subject is currently participating in any study with an investigational medicinal product or investigational device
Subject has any medical, neurological or psychiatric condition which, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study
Subject with Deep Brain Stimulation (DBS) device implant
Clareo Health | Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
